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Abstract
Background: Waardenburg syndrome (WS) is a very rare genetic disorder affecting the neural crest cells. Coexistence
of branch retinal vein occlusion (BRVO) and branch retinal artery occlusion (BRAO) in the same eye is also a rare finding.
Here we report a case of WS type 1 that was confirmed by a novel mutation with the finding of unilateral BRVO and
BRAO.
Case presentation: A 36-year-old, white-haired Korean man presented with a complaint of loss of vision in the inferior
visual field of his right eye and hearing loss. He had telecanthus with a medial eyebrow and a hypochromic left
iris. Funduscopy showed an ischemic change at the posterior pole in the right eye with sparing of the foveal center as
well as retinal hemorrhages and white patches along the superotemporal arcade. Fundus angiography revealed the
presence of both BRVO and BRAO, and optical coherence tomography showed thickening and opacification
of the retinal layers corresponding to the ischemic area. A blood workup revealed hyperhomocysteinemia and
the presence of antiphospholipid antibodies; both are suggestive as the cause of the BRVO and BRAO. Single
nucleotide polymorphism analysis confirmed a novel PAX3 mutation at 2q35 (c.91–95 ACTCC deletion causing
a frameshift). These findings confirmed a diagnosis of WS type 1.
Conclusions: WS is a heterogeneous inherited disorder of the neural crest cells that causes pigment abnormalities
and sensorineural hearing loss. This is the first report of unilateral BRVO and BRAO in a patient with WS. Furthermore,
the PAX3 mutation identified in this patient has not been reported previously.
Keywords: Waardenburg syndrome, PAX3 gene mutation, Hyperhomocysteinemia, Branch retinal vein occlusion,
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Background
Waardenburg syndrome (WS) is a rare heterogeneous
inherited disorder of the neural crest cells (NCC) [1, 2]
that causes abnormalities in NCC-derived melanocytes,
leading to pigment abnormalities and sensorineural
hearing loss. Read and Newton identified four types of
WS according to the additional symptoms present [3].
In their classification, type 1 (OMIM #193500) and type 2
(OMIM #193510) have similar features, but are distin-
guished by telecanthus, which is present only in type 1.
Musculoskeletal anomalies are found in type 3 (OMIM#
148820), while type 4 (OMIM #277580) is associated with
Hirschsprung disease. At the molecular level, six genes are
involved in this syndrome and have varying degrees of
frequency: PAX3 (encoding the paired box 3 transcription
factor) is associated with types 1 and 3, MITF (micro-
phthalmia-associated transcription factor) and SNAI2 (snail
homolog 2) with type 2, EDN3 (endothelin 3) and EDNRB
(endothelin receptor type B) with type 4, and SOX10 (Sry
bOX10 transcription factor) with types 2 and 4 [4].
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Coexistence of branch retinal vein occlusion (BRVO) and
branch retinal artery occlusion (BRAO) in the same eye is a
rare finding. Lee et al. reported 56 cases of coexisting arter-
ial insufficiency in a study of 308 eyes with BRVO [5]. Sub-
sequently, case series of patients with both BRAO and
BRVO and comorbid systemic associations were reported
[6, 7]. Commonly associated systemic comorbidities in-
cluded multiple cardiovascular risk factors, cardiac valve
disease, hyperhomocysteinemia, a hypercoagulable state,
systemic lupus, and vasculitis. Therefore, systemic evalu-
ation is routinely recommended in addition to appropriate
treatment in these patients. Coexisting BRVO and BRAO
has not been reported in a patient with WS.
Here we describe a patient with WS type 1 who was
found to have unilateral BRVO and BRAO and in whom
single nucleotide polymorphism analysis identified a
novel PAX3 mutation in the 2q35 region.
Case presentation
A 36-year-old, white-haired Korean man (Fig. 1. II-2:
Proband) visited the ophthalmology department com-
plaining of loss of vision in the inferior visual field of
his right eye. His face was characterized by lateral dis-
placement of the inner canthus of both eyes with a
medial eyebrow and a high broad nasal bridge (Fig. 2a).
His medical history was significant for paralysis of one
Fig. 1 Pedigree of a family with Waardenburg syndrome. The arrow
indicates the proband (II-2). The square indicates male sex and the
circle indicates female sex. The solid symbol represents a family
member with hearing loss and the clear symbol indicates a family
member without hearing loss. The symbol with a diagonal line
indicates a deceased family member
Fig. 2 The proband is a 37-year-old man with white hair, dystopia canthorum with a medial eyebrow (a), and a gray iris in the left eye (b)
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arm after a cerebral infarction 13 years earlier and
right-sided sensorineural hearing loss. His father
(Fig. 1. I-1), who had had hearing impairment, died of
a myocardial infarction in his 50s, and his brother
(Fig. 1. II-1) had bilateral hearing loss and heterochro-
mia iridis. His best corrected vision was 20/25 with
myopic correction (− 2.50 diopters) on the right and
20/20 with myopic correction (− 3.50 diopters) on the
left. His intraocular pressure was 15 mmHg in the
right eye and 13 mmHg in the left eye. A hypochromic
left iris (Fig. 2b) was observed on slit-lamp examin-
ation. Funduscopy showed an ischemic change at the
posterior pole with sparing of the foveal center along
with retinal hemorrhages and white patches along the
superotemporal arcade (Fig. 3a). Optical coherence
tomography revealed thickening and opacification of
the retinal layers corresponding to the ischemic area
(Fig. 3b). Both BRVO and BRAO were detected on
fluorescein angiography (Fig. 3c). An intravitreal
anti-vascular endothelial growth factor (Avastin®, bev-
acizumab) injection (1.25 mg in 0.05 mL) was admin-
istered in the right eye for macular edema. After
2 months, the patient’s macular edema was signifi-
cantly improved and his visual acuity was maintained
at 20/25.
Single nucleotide polymorphism analysis was performed
by comparing a peripheral blood sample with the NM_
181457 reference, and a PAX3 mutation was confirmed in
exon 2 on chromosome 2q35 (Fig. 4). An ACTCC deletion
was noted at c.91–95, causing a frameshift of protein
Thr31. A diagnosis of WS type 1 was made on the basis of
this genetic mutation and the patient’s clinical features. Fur-
ther biochemical workup revealed a raised serum homo-
cysteine level (28.3 μmol/L). Antiphospholipid antibodies,
including anticardiolipin and lupus anticoagulant, were also
detected. Other blood coagulation factors were in the
Fig. 3 a The right fundus, showing an ischemic change at the posterior pole with foveal sparing as well as retinal hemorrhages and white patches
along the superotemporal arcade. Choroidal hypopigmentation is visible in the left fundus. b An optical coherence tomography image
showing thickening and opacification of the retinal layers corresponding to the ischemic area. c On fundus angiography (FA), a nonperfused area is
seen superior to the macula because of the coexistence of branch retinal vein and artery occlusion. FA of the right eye shows a significant filling delay
of the branches of the superotemporal retinal artery with a corresponding ischemic area (23.1 s). Sludging of the retinal artery is apparent and the
retinal vein branches are tortuous and dilated (45.5 s). Capillary non-perfusion in the circulation of the superotemporal vein is observed. The perfusion
defect is still present with the absence of superotemporal retinal artery branches (355.7 s). Neovascularization is not observed
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normal range or negative. The electrocardiogram showed
no significant abnormality.
Discussion
WS was initially described as an autosomal dominant
disorder associated with depigmentation abnormalities
and sensorineural hearing loss [1, 2, 4]. Other clinical
manifestations, including dysmorphic craniofacial fea-
tures [2, 8], upper limb abnormalities [2, 9], Hirsch-
sprung disease [3, 10], and neurologic defects [11], have
been reported with variable frequency. WS is now
known to consist of a group of genetically heterogenous
subtypes, and not all cases are inherited in a dominant
manner. Given that the syndrome is caused by a genetic
disorder affecting NCCs, the melanocytes of the skin
and inner ear, peripheral and enteric nervous systems,
and some of the craniofacial and skeletal tissues can in
theory be affected [12, 13]. All six genes (PAX3, MITF,
EDN3, EDNRB, SOX10, and SNAI2) known to cause
WS [4] are involved in a complex interplay relating to
the differentiation and function of melanocytes. Hetero-
zygous mutations in PAX3 are known to be responsible
for most cases of WS types 1 and 3.
In this case, we identified a novel PAX3 mutation (c.91–
95 ACTCC deletion causing p.Thr31fs) in exon 2, which
has not been reported previously. The pathogenicity of
this frameshift mutation was validated by in silico predic-
tion using Combined Annotation Dependent Depletion
(CADD) version 1.4 [14]. The mutation was predicted to
be highly deleterious for PAX3 (CADD score = 34). It is
well known that PAX3 mutation is likely to cause WS type
1 [15–22]. The clinical characteristics in our patient sup-
ported a diagnosis of WS type 1, i.e., pigment abnormal-
ities of the hair and left eye, congenital hearing loss, and
dystopia canthorum. No musculoskeletal, neurologic, or
intestinal anomalies were detected. The main limitation of
this report is that the underlying pattern of inheritance of
WS in the patient’s family could not be investigated.
However, we constructed the family pedigree based on
the hearing-impaired phenotype, which suggested that
the de novo mutation (c.91-95delACTCC) identified in
PAX3 was the likely cause of genetic transmission of
hearing loss in the patient’s family. In addition to family
genotyping, further studies that include functional ana-
lysis are required to explore the genetic mechanism of
this novel mutation.
It is of interest that our patient had both BRVO with
BRAO in the eye contralateral to the depigmented left
eye. Although the relationship is not clear, the angio-
graphic findings suggest that the initiating event was
Fig. 4 Results of single nucleotide polymorphism (SNP) analysis revealed a PAX3 mutation in exon 2 on chromosome 2q35. An ACTCC deletion at
c.91–95 caused a frameshift of protein Thr31. The SNP analysis was carried out according to the recommendations of the manufacturer (Applied
Biosystems, CA, USA). Polymerase chain reaction products were prepared after optimization, amplification, and purification processes. The 96-
capillary 3730xl DNA Analyzer (Applied Biosystems) was used for high-throughput SNP mapping and discovery. Combined Annotation
Dependent Depletion (CADD) v1.4 was used to predict the pathogenicity of variants. The identified novel mutation was highly deleterious for
PAX3 (CADD score = 34)
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retinal vein occlusion followed by stasis of blood flow.
An elevation of intraluminal capillary pressure caused by
a patent central retinal artery seemed to result in BRAO
in the same quadrant as the BRVO. Considering the fa-
vorable visual outcome in this patient after 2 months of
follow-up, arterial insufficiency rather than frank ob-
struction seems more likely. Laboratory investigations
identified hyperhomocysteinemia [23, 24] and antipho-
spholipid antibodies [25, 26] as the possible cause of the
unilateral BRVO and BRAO in this young patient. Kadoi
et al. have previously reported BRVO of a hypochromic
eye in a patient with WS that was considered most likely
to be caused by systemic hypertension [27].
In vitro and animal studies have shown that the
homocysteine level in the embryonic stage affects the
expression of PAX [28, 29]. The relationship between
homocysteine and PAX3 mutation in WS is unclear.
However, it is possible that the homocysteine level
could be an environmental factor contributing to the
variable clinical expression and familial penetrance of
phenotypes in WS.
Conclusion
We have encountered a young male patient who pre-
sented with a unilateral visual field defect associated
with both BRVO and BRAO in his right eye. The diag-
nosis of WS type 1 was confirmed by his characteristic
clinical features and detection of a novel PAX3 muta-
tion at 2q35 (c.91–95 ACTCC deletion). This report is
the first to describe coexistence of BRVO and BRAO in
association with hyperhomocysteinemia and antipho-
spholipid antibodies in a patient with WS. Further stud-
ies are needed to identify the association between WD
and hyperhomocysteinemia.
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